Literature DB >> 23804264

Gut microbiota and type 1 diabetes.

Outi Vaarala1.   

Abstract

The gut immune system has a key role in the development of autoimmune diabetes, and factors that control the gut immune system are also regulators of beta-cell autoimmunity. Gut microbiota modulate the function of the gut immune system by their effect on the innate immune system, such as the intestinal epithelial cells and dendritic cells, and on the adaptive immune system, in particular intestinal T cells. Due to the immunological link between gut and pancreas, e.g. the shared lymphocyte homing receptors, the immunological changes in the gut are reflected in the pancreas. According to animal studies, changes in gut microbiota alter the development of autoimmune diabetes. This has been demonstrated by antibiotics that induce changes in the gut microbiota. Furthermore, gut-colonizing microbes may modify the incidence of autoimmune diabetes in animal models. Deficient toll-like receptor (TLR) signaling, mediating microbial stimulus in immune cells, prevents autoimmune diabetes, which appears to be dependent on alterations in the intestinal microbiota. Although few studies have been conducted in humans, recent studies suggest that the abundance of Bacteroides and lack of butyrate-producing bacteria in fecal microbiota are associated with beta-cell autoimmunity and type 1 diabetes. It is possible that altered gut microbiota are associated with immunological aberrancies in type 1 diabetes. The changes in gut microbiota could lead to alterations in the gut immune system, such as increased gut permeability, small intestinal inflammation, and impaired tolerance to food antigens, all of which are observed in type 1 diabetes. Poor fitness of gut microbiota could explain why children who develop type 1 diabetes are prone to enterovirus infections, and do not develop tolerance to cow milk antigens. These candidate risk factors of type 1 diabetes may imply an increased risk of type 1 diabetes due to the presence of gut microbiota that do not support health. Despite the complex interaction of microbiota, host, environment, and disease mechanisms, gut microbiota are promising novel targets in the prevention of type 1 diabetes.

Entities:  

Mesh:

Year:  2012        PMID: 23804264      PMCID: PMC3740694          DOI: 10.1900/RDS.2012.9.251

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN: 1613-6071


  55 in total

1.  Endocrine self and gut non-self intersect in the pancreatic lymph nodes.

Authors:  Shannon J Turley; Je-Wook Lee; Nick Dutton-Swain; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-29       Impact factor: 11.205

2.  Th17 cells in inflammatory conditions.

Authors:  Anne Cooke
Journal:  Rev Diabet Stud       Date:  2006-08-10

3.  Regulatory T cells: stability revisited.

Authors:  Samantha L Bailey-Bucktrout; Jeffrey A Bluestone
Journal:  Trends Immunol       Date:  2011-05-27       Impact factor: 16.687

4.  Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.

Authors:  June L Round; Sarkis K Mazmanian
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

5.  Butyrate and type 1 diabetes mellitus: can we fix the intestinal leak?

Authors:  Nan Li; Marguerite Hatch; Clive H Wasserfall; Martha Douglas-Escobar; Mark A Atkinson; Desmond A Schatz; Josef Neu
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-10       Impact factor: 2.839

6.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.

Authors:  Luying Peng; Zhong-Rong Li; Robert S Green; Ian R Holzman; Jing Lin
Journal:  J Nutr       Date:  2009-07-22       Impact factor: 4.798

7.  Altered phenotype of peripheral blood dendritic cells in pediatric type 1 diabetes.

Authors:  Janne K Nieminen; Jukka Vakkila; Harri M Salo; Nina Ekström; Taina Härkönen; Jorma Ilonen; Mikael Knip; Outi Vaarala
Journal:  Diabetes Care       Date:  2012-07-11       Impact factor: 19.112

8.  Inflammatory tendencies and overproduction of IL-17 in the colon of young NOD mice are counteracted with diet change.

Authors:  Catharina Alam; Suvi Valkonen; Vindhya Palagani; Jari Jalava; Erkki Eerola; Arno Hänninen
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

9.  Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes.

Authors:  Christopher T Brown; Austin G Davis-Richardson; Adriana Giongo; Kelsey A Gano; David B Crabb; Nabanita Mukherjee; George Casella; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Tuula Simell; Olli Simell; Josef Neu; Clive H Wasserfall; Desmond Schatz; Mark A Atkinson; Eric W Triplett
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

10.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Authors:  Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky
Journal:  Nature       Date:  2008-09-21       Impact factor: 49.962

View more
  27 in total

1.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

Review 2.  Risk of Type 1 Diabetes in the Offspring Born through Elective or Non-elective Caesarean Section in Comparison to Vaginal Delivery: a Meta-Analysis of Observational Studies.

Authors:  Justine Tanoey; Amit Gulati; Chris Patterson; Heiko Becher
Journal:  Curr Diab Rep       Date:  2019-11-11       Impact factor: 4.810

3.  Different immunological responses to early-life antibiotic exposure affecting autoimmune diabetes development in NOD mice.

Authors:  Youjia Hu; Ping Jin; Jian Peng; Xiaojun Zhang; F Susan Wong; Li Wen
Journal:  J Autoimmun       Date:  2016-05-10       Impact factor: 7.094

4.  Polysaccharide A-Dependent Opposing Effects of Mucosal and Systemic Exposures to Human Gut Commensal Bacteroides fragilis in Type 1 Diabetes.

Authors:  M Hanief Sofi; Benjamin M Johnson; Radhika R Gudi; Amy Jolly; Marie-Claude Gaudreau; Chenthamarakshan Vasu
Journal:  Diabetes       Date:  2019-07-16       Impact factor: 9.461

Review 5.  On the pathogenesis of insulin-dependent diabetes mellitus: the role of microbiota.

Authors:  Elena Gianchecchi; Alessandra Fierabracci
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

6.  Bacterial Flora Changes in Conjunctiva of Rats with Streptozotocin-Induced Type I Diabetes.

Authors:  Chao Yang; Yuda Fei; Yali Qin; Dan Luo; Shufei Yang; Xinyun Kou; Yingxin Zi; Tingting Deng; Ming Jin
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 7.  From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.

Authors:  Ayman F Refaie; Batoul L Elbassiouny; Malgorzata Kloc; Omaima M Sabek; Sherry M Khater; Amani M Ismail; Rania H Mohamed; Mohamed A Ghoneim
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 8.  Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies.

Authors:  Camila Leal-Lopes; Fernando J Velloso; Julia C Campopiano; Mari C Sogayar; Ricardo G Correa
Journal:  J Diabetes Res       Date:  2015-08-06       Impact factor: 4.011

9.  Higher diversity in fungal species discriminates children with type 1 diabetes mellitus from healthy control.

Authors:  Beata Kowalewska; Katarzyna Zorena; Małgorzata Szmigiero-Kawko; Piotr Wąż; Małgorzata Myśliwiec
Journal:  Patient Prefer Adherence       Date:  2016-04-21       Impact factor: 2.711

10.  Effect of prebiotic intake on gut microbiota, intestinal permeability and glycemic control in children with type 1 diabetes: study protocol for a randomized controlled trial.

Authors:  Josephine Ho; Raylene A Reimer; Manpreet Doulla; Carol Huang
Journal:  Trials       Date:  2016-07-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.